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Abstract
A recent study proposed new TNM groupings for better survival discrimination among 
stage groups for medullary thyroid carcinoma (MTC) and validated these groupings 
in a population-based cohort in the United States. However, it is unknown how well 
the groupings perform in populations outside the United States. Consequently, we 
conducted the first population-based study aiming to evaluate if the recently proposed 
TNM groupings provide better survival discrimination than the current American Joint 
Committee on Cancer (AJCC) TNM staging system (seventh and eighth edition) in a 
nationwide MTC cohort outside the United States. This retrospective cohort study included 
191 patients identified from the nationwide Danish MTC cohort between 1997 and 2014. In 
multivariate analysis, hazard ratios for overall survival under the current AJCC TNM staging 
system vs the proposed TNM groupings with stage I as reference were 1.32  
(95% CI: 0.38–4.57) vs 3.04 (95% CI: 1.38–6.67) for stage II, 2.06 (95% CI: 0.45–9.39) vs 3.59  
(95% CI: 1.61–8.03) for stage III and 5.87 (95% CI: 2.02–17.01) vs 59.26 (20.53–171.02) 
for stage IV. The newly proposed TNM groupings appear to provide better survival 
discrimination in the nationwide Danish MTC cohort than the current AJCC TNM staging. 
Adaption of the proposed TNM groupings by the current AJCC TNM staging system may 
potentially improve accurateness in survival discrimination. However, before such an 
adaption further population-based studies securing external validity are needed.
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Introduction
Medullary thyroid carcinoma (MTC) is a rare 
neuroendocrine tumor with an incidence of 0.19 per 
100,000 per year and a prevalence of 3.8 per 100,000 
inhabitants. MTC is divided into a sporadic and 
hereditary type accounting for approximately 75 and 
25%, respectively (1).
MTC can display a highly variable biological behavior, 
ranging from indolent to very aggressive (2, 3, 4). This 
necessitates strong outcome predictors, for example, 
the American Joint Committee on Cancer (AJCC) TNM 
staging system (5, 6, 7). The current AJCC TNM version 
(seventh and eighth edition) by large mirrors that for 
papillary and follicular thyroid carcinoma in spite of 
the fact that MTC differs considerably from the other 
histological subtypes (2). For this and other reasons 
several studies have questioned the accuracy of the AJCC 
TNM staging system for MTC and thus proposed different 
modifications (3, 8, 9, 10).
Based on data from the US National Cancer Database 
(11), a large population-based study recently proposed 
new TNM groupings for better discrimination of 
mortality risk among the stage groups (2). Application 
of the proposed TNM groupings to a data set from the 
Surveillance, Epidemiology, and End Results Program (12) 
demonstrated a better stage separation compared to that of 
the current AJCC TNM staging system (2). In brief, overall 
differences between the current AJCC TNM staging system 
and the newly proposed groupings include categorization 
of patients with small tumors and local metastases in 
stages I–II and inclusion of only patients with distant 
metastases in stage IV in the proposed TNM groupings. It 
is however unknown how well these groupings perform 
in populations outside the United States.
Consequently, we conducted the first population-
based study aiming to evaluate if the recently proposed 
TNM groupings provide better survival discrimination 
than the current AJCC TNM staging system in a nationwide 
MTC cohort outside the United States.
Patients and methods
Patients
This retrospective cohort study included 191 unique 
patients diagnosed with MTC in Denmark between 
January 1, 1997, and December 31, 2014.
An MTC cohort, initially comprising 476 patients 
diagnosed with MTC in Denmark between January 1960 
and December 2014, was constructed through three 
nationwide registries: the Danish Thyroid Cancer 
Database, the Danish Cancer Registry and the Danish 
Pathology Register (13, 14, 15). This has been described 
in detail previously (1, 16). The Danish MTC cohort is 
subdivided by year of diagnosis into an uncertain period 
(1960–1996) where complete coverage could not be 
guaranteed and into a nationwide period (1997–2014) 
where coverage of the entire country was considered 
complete. For the purpose of this study, we extracted 
the 224 patients diagnosed in the nationwide period. 
Of the 224 patients, four were excluded as they were 
diagnosed by autopsy. Furthermore, for the best possible 
replication, our cohort was trimmed according to the 
cohort from the study proposing new TNM groupings 
(2). We therefore additionally excluded 29 patients: 
those <18  years at diagnosis (n = 10) (16, 17, 18, 19, 
20), those with insufficient TNM data (n = 2) and those 
who underwent less surgery than hemithyroidectomy 
(n = 17). This resulted in 191 patients with histologically 
verified MTC.
The investigation was approved by the Danish Health 
Authority (3-3013-395/3) and the Danish Data Protection 
Agency (18/17801). Once approved by the former, 
patient consent is not necessary according to the Danish 
legislation.
Methods
Data were provided by the Danish Thyroid Cancer 
Database (13). Where this was insufficient, data were 
drawn from the Danish Cancer Registry (14), the Danish 
Pathology Register (15) or medical records.
Covariates were age, sex, year of diagnosis and 
TNM stage. Also patients were classified according to 
MTC type as sporadic or hereditary. This was primarily 
based on the absence or presence of rearranged during 
transfection (RET) germline mutations. RET testing and 
MTC classification has been described elsewhere (1, 21). 
Staging was performed according to the current AJCC 
TNM staging system (seventh and eighth edition) (22, 23) 
and according to the newly proposed TNM groupings (2) 
(Table 1). Staging was based on clinical and pathological 
assessment. If there was a discrepancy, pathological 
staging overruled clinical.
Survival
Outcomes were overall and disease-specific survival. 
Survival time was calculated as the time from MTC 
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diagnosis until death, emigration or last follow-up 
(January 1, 2018), whichever came first. For calculation of 
overall and disease-specific survival, all deaths and deaths 
due to MTC were considered as an event, respectively.
Statistical analysis
Continuous variables are reported as median with 
interquartile range or mean with standard deviation 
depending on distribution. Survival data were analyzed 
by the Kaplan–Meier method. Cox proportional hazards 
regression model was employed for multivariate analyses. 
The Akaike criterion was used to estimate the relative 
quality of statistical models. P values below 0.05 were 
considered significant. Multiple testing was adjusted by 
the Bonferroni method (24). All analyses were done using 
Stata 15.1 (StataCorp).
Results
A total of 191 patients were included in the study. Patient 
characteristics are shown in Table 2. The overall female–
male ratio was 1.51 (95 CI: 1.10–1.95). In the 42 patients 
with hereditary MTC, the following RET mutations were 
detected: C611W (n = 3), C611Y (n = 29), C618F (n = 1), 
C618Y (n = 3), C620R (n = 2), C634R (n = 1), C634Y + Y791F 
(n = 1), V804M (n = 1) and M918T (n = 1). Several of these 
families have been reported earlier (19, 25, 26, 27, 28, 29).
Under the current AJCC TNM staging system 51 
(27%), 38 (20%), 16 (8%) and 86 (45%) were classified in 
stages I, II, III and IV, respectively. Among the patients in 
stages I, II, III and IV, 51 (100%), 9 (24%), 2 (13%) and 
9 (10%) remained in the same group under the proposed 
TNM groupings. The remaining patients were reclassified 
to lower stage groups. Thus, the distribution of patients 
under the proposed TNM groupings was 88 (46%) in stage 
I, 54 (28%) in stage II, 40 (21%) in stage III and 9 (5%) in 
stage IV (Table 1).
Survival
Median follow-up time was 7.15 years (interquartile range, 
0.52–20.59). At last follow-up, 59 patients had died. Of 
these, 37 had died from MTC, while 22 died from other 
causes.
Overall and disease-specific survival according to 
the current AJCC TNM staging and the proposed TNM 
groupings are depicted in Fig.  1 and Table  3. Hazard 
ratios for adjusted overall survival based on the current 
AJCC TNM staging and the proposed TNM groupings are 
presented in Table 4.
Table 1 Distribution of 191 patients with medullary thyroid 
carcinoma in Denmark 1997–2014 according to the currenta 
and proposed TNM staging systemb.
Stage Current n (%) Proposed n (%)
I T1N0M0 51 (27) T1N0-1aM0
T2N0M0
88 (46)
II T2-3N0M0 38 (20) T1N1bM0
T2N1a-1bM0
T3N0M0
54 (28)
III T1-3N1aM0 16 (8) T3N1a-1bM0
T4N0-1bM0
40 (21)
IV T1-3N1bM0
T4N0-1bM0
T1-4N0-1bM1
86 (45) T1-4N0-1bM1 9 (5)
aStaging was based on the American Joint Committee on Cancer 7th and 
8th edition (22, 23); bstaging was based on newly proposed groupings (2).
M, metastasis; N, node; T, tumor.
Table 2 Characteristics of 191 patients with medullary 
thyroid carcinoma in Denmark 1997–2014.
Characteristics n (%)
At diagnosis
 Age, mean (s.d.) (years) 53 (16)a
 Sex
  Female 115 (60)
  Male 76 (40)
 MTC type
  Sporadic 149 (78)
  Hereditary 42 (22)
 T category
  T1 81 (42)
  T2 52 (27)
  T3 24 (13)
  T4 34 (18)
 N category
  N0 91 (48)
  N1a 20 (10)
  N1b 80 (42)
 M category
  M0 182 (95)
  M1 9 (5)
 Current TNM stagingb
  I 51 (27)
  II 38 (20)
  III 16 (8)
  IV 86 (45)
 Thyroid surgery
  Total thyroidectomy 188 (98)
  Hemithyroidectomy 3 (2)
aStandard deviation; bstaging was based on the American Joint Committee 
on Cancer 7th and 8th edition (22, 23).
M, metastasis; MTC, medullary thyroid carcinoma; N, node; s.d., standard 
deviation; T, tumor.
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When staging was based on the current AJCC TNM 
staging system, adjusted overall survival did not differ 
significantly for stage I vs II (P = 0.662), stage II vs III 
(P = 0.522) or stage III vs IV (P = 0.082). Meanwhile, 
when using the proposed TNM groupings, adjusted 
overall survival was significantly different for stage I vs 
II (P = 0.006) and stage III vs IV (P < 0.001), but not stage 
II vs III (P = 0.605). Similar results were obtained after 
Bonferroni correction.
Discussion
In this nationwide study, we compared the current AJCC 
TNM staging system to the newly proposed TNM groupings 
and found that the latter provides better differentiation of 
mortality risk for stage I vs II and stage III vs IV.
Limitations
Our sample size is relatively small, providing lesser 
statistical power to detect differences in survival among 
the stage groups. We cannot exclude that this was the 
case for stage II vs III under the proposed TNM groupings. 
However, it was no issue in the comparison of stage I vs 
II and stage III vs IV, as significant differences in survival 
were seen in both cases, even after Bonferroni correction.
Our adjusted analysis of survival did not include the 
covariates: annual income, insurance and hospital type 
seen in the study of the proposed TNM groupings (2). 
Figure 1
Overall and disease-specific survival in 191 patients with medullary thyroid carcinoma in Denmark 1997–2014 according to the currenta and proposed 
TNM staging systemb. M, metastasis; N, node; T, tumor. aStaging was based on the American Joint Committee on Cancer 7th and 8th edition (22, 23). 
bStaging was based on newly proposed groupings (2).
Table 3 Five-year survival in 191 patients with medullary 
thyroid carcinoma in Denmark 1997–2014 according to the 
currenta and proposed TNM staging systemb.
Stage
Overall survival Disease-specific survival
Current Proposed Current Proposed
5-year (95% CI) 5-year (95% CI) 5-year (95% CI) 5-year (95% CI)
I 92 (79–97) 94 (86–98) 100 99 (92–100)
II 95 (81–99) 81 (68–89) 97 (82–100) 88 (75–94)
III 94 (63–99) 61 (44–75) 94 (63–99) 71 (54–83)
IV 64 (53–73) 22 (3–51) 71 (60–80) 22 (3–51)
aStaging was based on the American Joint Committee on Cancer 7th and 
8th edition (22, 23); bstaging was based on newly proposed groupings (2).
T, tumor; N, node; M, metastasis.
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However, adjustment for these covariates in a Danish 
setting would seem redundant, partly because medical 
care is free for all inhabitants, treatment of thyroid cancer 
is centralized to university hospitals only and partly 
because income and insurance in earlier multivariate 
analysis have been reported as non-significant predictors 
of overall survival (30).
For the purpose of this study, our cohort was trimmed 
according to the study cohort of the investigation proposing 
the new TNM groupings. For example, the investigation 
excluded patients <18 years at diagnosis from their study 
cohort (2) although inclusion may have been an option 
(31). Similarly, we excluded this patient group from our 
cohort. Thus, along with the other exclusion criteria, 
the reproducibility of the proposed TNM groupings in 
an unselected MTC population may be compromised. 
However, when reanalyzing data for the 218 patients with 
pertinent data from our initial cohort of 220 unselected 
patients, we still find a significant difference in adjusted 
overall survival for stage I vs II (P = 0.014) and stage III vs 
IV (P < 0.001) under the proposed TNM groupings.
Survival
Our results of better survival discrimination for stage I vs 
II and stage III vs IV under the proposed TNM groupings 
are in agreement with the study proposing the new 
groupings (2). While better distinction between stage II 
and III under the proposed TNM groupings compared to 
the current AJCC TNM staging system may be somewhat 
dubious in our data set, it is indisputable for stage III vs IV. 
Presumably, this is explained by the fact that stage IV in 
the proposed TNM groupings only includes patients with 
distant metastases, while the current AJCC TNM staging 
system also includes patients with T4 or N1b disease 
having no evidence of distant metastases (Table 1). Thus, 
the current AJCC TNM staging system seems to attenuate 
the significance of distant metastases, despite the fact that 
several population-based studies report distant metastases 
as one of the absolute strongest prognostic indicators for 
survival in multivariate analysis (7, 32, 33, 34, 35, 36).
In fact, stage IV has previously consisted of patients 
with distant metastases only (37) as in the proposed TNM 
groupings (2). This was changed in 2002 in the sixth 
edition of the AJCC TNM staging system, where stage IV 
was expanded to also include patients with T4 or N1b 
disease regardless of distant metastases status (38). Later 
an institutional study, investigating the survival of 173 
MTC patients according to the fifth and sixth edition of 
the AJCC TNM staging system found that patients with 
stage III and IV disease had similar disease-free survival 
and overall survival under the sixth edition. This led 
to the conclusion that the sixth edition of the AJCC 
TNM staging system appeared inadequate, especially for 
patients with stage IV disease (3) Stage IV, however, has 
not been changed since 2002.
In our study, the proposed TNM groupings also 
demonstrated better survival distinction than the current 
AJCC TNM staging system for stage I vs II. This may be 
explained by the downstaging of small tumors (T1–2) with 
lateral neck metastases (N1b) from stage IV in the current 
AJCC TNM staging system to stage II in the proposed 
TNM groupings (Table 1).
Conclusion
The newly proposed TNM groupings appear to provide 
better survival discrimination in the nationwide Danish 
MTC cohort than the current AJCC TNM staging system. 
Adaption of the proposed TNM groupings by the current 
AJCC TNM staging system may potentially improve 
accurateness in survival discrimination. However, before 
such an adaption, further population-based studies 
securing external validity are needed.
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